Celltrion, Inc., together with its subsidiaries, develops and produces drugs based on proteins for the treatment of oncology in South Korea. The company markets bio pharmaceuticals; generic pharmaceuticals; and covid-19 test kits. Its antibody biosimilar pipeline includes CT-P39 that is in phase 3 clinical trial for the treatment of asthma and urticaria; CT-P41, which is in phase 3 clinical trial for the treatment of osteoporosis and bone loss; CT-P42, which is in phase 3 clinical trial for the treatment of diabetic macular edema; and CT-P43 that is in phase 3 clinical trial for the treatment of psoriasis, crohn's disease, and ulcerative colitis. The company also offers CT-P47, which is in phase 3 clinical trial for the treatment of rheumatoid arthritis; and CT-P53 that is is in phase 3 clinical trial for the treatment of multiple sclerosis. Celltrion, Inc. was founded in 2002 and is headquartered in Incheon, South Korea.

Celltrion Inc

Mr. Hyong-Gi  Kim

CEO & Internal Director

Mr. Woo-Sung  Kee

Jin-seok  Seo

Co-CEO & Inside Co-Chairman of the Board

Mr. Stephen  Yeum

Founder

Mr. Min-Cheol  Shin

Director of Finance

Mr. Ji-Hoon  Choi

Director of Legal Affairs

068270's next earnings is on February 26, 2025 (After Market Close)

068270's latest dividend is 500 KRW on December 27, 2023

Celltrion Inc (068270) Stock Analysis, Discussion Forum and Financial Metrics - KRX Exchange

Celltrion Inc (068270) Earnings Report Date and History | KRX

068270's next earnings is on February 26, 2025 (After Market Close)

When is the earnings report for 068270?

068270 Earnings History

068270's latest dividend is 500 KRW on December 27, 2023

068270 Stock Discussion Forum and Message Board

News for KRX: 068270